Cardiovascular Renal & Metabolic (CRM) Diseases Market - 2024-2033

October 2025 | 229 pages | ID: C936F78C4846EN
DataM Intelligence

Abstracts

The Cardiovascular Renal & Metabolic (CRM) Diseases Market was valued at US$ 298.73 Billion in 2024 and is anticipated to reach US$ 451.87 Billion by 2033, at a CAGR of 0.048 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cardiovascular Renal & Metabolic (CRM) Diseases Market.

This report delivers a comprehensive overview of the Cardiovascular Renal & Metabolic (CRM) Diseases Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cardiovascular Renal & Metabolic (CRM) Diseases Market. The Cardiovascular Renal & Metabolic (CRM) Diseases Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Cardiovascular Renal & Metabolic (CRM) Diseases Market Scope:

Key Players

• Novo Nordisk
• Eli Lilly and Company
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Johnson & Johnson
• Bayer AG
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• Amgen Inc.

Major Highlights

This report delivers a comprehensive overview of the Cardiovascular Renal & Metabolic (CRM) Diseases Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cardiovascular Renal & Metabolic (CRM) Diseases Market. The Cardiovascular Renal & Metabolic (CRM) Diseases Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Treatment Type
2.5. Snippet by End-User
2.6. Snippet by Region

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Outcome-Driven Therapeutic Innovation
    3.1.1.2. Strategic Collaborations & Cross-Industry Partnerships
  3.1.2. Restraints
    3.1.2.1. Limited Awareness and Underdiagnosis of Early-Stage CKD & Metabolic Syndrome
    3.1.2.2. High Treatment Costs and Reimbursement Gaps
  3.1.3. Opportunity
    3.1.3.1. Expansion of Multi-Organ Indications
    3.1.3.2. Rapid Growth in Obesity and Weight-Management Therapeutics
  3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

4.1. Market Leaders and Pioneers
  4.1.1. Emerging Pioneers and Prominent Players
  4.1.2. Established Leaders with the Largest Marketing Brand
  4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
  4.3.1. North America
  4.3.2. Europe
  4.3.3. Asia Pacific
  4.3.4. South America
  4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
  4.4.1. Threat of New Entrants
  4.4.2. Threat of Substitutes
  4.4.3. Bargaining Power of Suppliers
  4.4.4. Bargaining Power of Buyers
  4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
  4.5.1. Raw material Suppliers
  4.5.2. Manufacturers
  4.5.3. Regulatory Approvals/Certifications
  4.5.4. Distributors
  4.5.5. End-Users
4.6. Patent Analysis
4.7. Unmet Needs and Gaps
4.8. Recommended Strategies for Market Entry and Expansion
4.9. Pricing Analysis and Price Dynamics

5. CARDIOVASCULAR-RENAL-METABOLIC (CRM) DISEASES MARKET, BY DISEASE TYPE

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  5.1.2. Market Attractiveness Index, By Disease Type
5.2. Cardiovascular Diseases*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  5.2.3. Ischemic Heart Disease
  5.2.4. Heart failure
  5.2.5. Hypertension
  5.2.6. Stroke
  5.2.7. Others
5.3. Renal Diseases
  5.3.1. Chronic Kidney Disease (CKD)
  5.3.2. End-Stage Renal Disease (ESRD)
  5.3.3. Acute Kidney Injury
  5.3.4. Others
5.4. Metabolic Disorders
  5.4.1. Diabetes
  5.4.2. Obesity / Weight Management
  5.4.3. Dyslipidemia
  5.4.4. Metabolic Syndrome / NASH / MAFLD

6. CARDIOVASCULAR-RENAL-METABOLIC (CRM) DISEASES MARKET, BY TREATMENT TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Therapeutics*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  6.2.3. GLP-1 Receptor Agonists
  6.2.4. SGLT2 Inhibitors
  6.2.5. Calcium Channel Blockers
  6.2.6. Beta-Blockers
  6.2.7. Statins
  6.2.8. Antiplatelets
  6.2.9. Diuretics
  6.2.10. Others
6.3. Devices
  6.3.1. Cardiovascular Devices
    6.3.1.1. Implantable Cardiac Devices
    6.3.1.2. Ventricular Assist Devices
    6.3.1.3. Coronary Stents / Drug-Eluting Stents
    6.3.1.4. Transcatheter Valves
    6.3.1.5. Blood Pressure Monitors
  6.3.2. Renal Dialysis Devices
  6.3.3. Metabolic Devices
    6.3.3.1. Continuous Glucose Monitors
    6.3.3.2. Insulin Pumps / Patch Pumps
    6.3.3.3. Closed-Loop Artificial Pancreas Systems
    6.3.3.4. Others
6.4. Others

7. CARDIOVASCULAR-RENAL-METABOLIC (CRM) DISEASES MARKET, BY END-USER

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Homecare Settings
7.5. Academic and Research Institutes
7.6. Others

8. CARDIOVASCULAR-RENAL-METABOLIC (CRM) DISEASES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  8.1.2. Market Attractiveness Index, By Region
8.2. North America
  8.2.1. Introduction
  8.2.2. Key Region-Specific Dynamics
  8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    8.2.6.1. U.S.
    8.2.6.2. Canada
    8.2.6.3. Mexico
8.3. Europe
  8.3.1. Introduction
  8.3.2. Key Region-Specific Dynamics
  8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    8.3.6.1. Germany
    8.3.6.2. UK
    8.3.6.3. France
    8.3.6.4. Spain
    8.3.6.5. Italy
    8.3.6.6. Rest of Europe
8.4. Asia-Pacific
  8.4.1. Introduction
  8.4.2. Key Region-Specific Dynamics
  8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    8.4.6.1. China
    8.4.6.2. India
    8.4.6.3. Japan
    8.4.6.4. South Korea
    8.4.6.5. Rest of Asia-Pacific
8.5. South America
  8.5.1. Introduction
  8.5.2. Key Region-Specific Dynamics
  8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    8.5.6.1. Brazil
    8.5.6.2. Argentina
    8.5.6.3. Rest of South America
8.6. Middle East and Africa
  8.6.1. Introduction
  8.6.2. Key Region-Specific Dynamics
  8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking

10. COMPANY PROFILES

10.1. Novo Nordisk*
  10.1.1. Company Overview
  10.1.2. Product Portfolio
    10.1.2.1. Product Description
    10.1.2.2. Product Key Performance Indicators (KPIs)
  10.1.3. Financial Overview
    10.1.3.1. Company Revenue
    10.1.3.2. Geographical Revenue Shares
    10.1.3.3. Revenue Forecasts
  10.1.4. Key Developments
    10.1.4.1. Mergers & Acquisitions
    10.1.4.2. Key Product Development Activities
    10.1.4.3. Regulatory Approvals, etc.
    10.1.4.4. SWOT Analysis
10.2. Eli Lilly and Company
10.3. AstraZeneca
10.4. Boehringer Ingelheim International GmbH
10.5. Johnson & Johnson
10.6. Bayer AG
10.7. Merck & Co., Inc.
10.8. Novartis AG
10.9. Sanofi
10.10. Amgen Inc. (LIST NOT EXHAUSTIVE)

11. ASSUMPTIONS AND RESEARCH METHODOLOGY

11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation

12. APPENDIX

12.1. About Us and Services
12.2. Contact Us